ArticleJournal of bacteriology2025
Functional analysis of thiamine pyrophosphate-responsive riboswitches in human bacterial pathogens of the ESKAPE group using a dual-luciferase reporter gene assay.
Article in Journal of bacteriology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Thiamine pyrophosphate (TPP)-responsive riboswitches are genetic elements in bacteria that regulate the expression of genes coding for proteins involved in the biosynthesis and transport of thiamine (vitamin B IMPORTANCE: Riboswitches are RNA molecules that control important processes in bacteria. Infections with pathogens of the ESKAPE group are common, and we are trying to find new ways to fight these bacteria. Small molecules can be designed to bind to riboswitches and optimally block their activity. In the present work, we have analyzed the thiamine pyrophosphate (TPP) riboswitches of ESKAPE pathogens with respect to small molecule binding. For this purpose, we developed a dual-luciferase reporter gene assay. Most of the predicted TPP riboswitches were indeed functional regulators and are thus targets for new anti-infectives. The small molecule pyrithiamine does not block all TPP riboswitches tested, and we found a structural basis for this behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.